Brexucabtagene contains a murine extracellular scFv of the FMC63 monoclonal antibody that binds to CD19 on tumor cells followed by a human CD28α hinge and transmembrane domain fused to the costimulatory molecule CD28 and the T cell activation domain CD3ζ chain (40). Here, CD247 is linked to neoplasm.